Luspatercept for Lower Risk Myelodysplastic Syndromes (MDS)
This study is looking at a drug called luspatercept for people with lower risk myelodysplastic syndromes (MDS). MDS is a group of disorders where your bone marrow doesn't make enough healthy blood cells. The main goal is to see how safe luspatercept is and if it can help reduce the number of blood transfusions you might need. Researchers will also look at how well the drug works in people who are transfusion-independent (don't need transfusions) and those who are transfusion-dependent (need transfusions). You could be eligible if you are 18 or older and have been diagnosed with lower risk MDS.
- Study design
- This is a pilot, open-label study, meaning both you and your doctors will know you are receiving luspatercept. It plans to enroll 10 participants.
- What's involved
- You would receive luspatercept by injection under the skin. The study will assess side effects for about one year.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will track side effects through study completion, which is an average of one year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Guillermo Garcia-Manero, M D · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0through study completion; an average 1 year.